ArticlePloS one2014
Comparison of human induced pluripotent stem-cell derived cardiomyocytes with human mesenchymal stem cells following acute myocardial infarction.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Induced Pluripotent Stem Cell-Derived Cardiomyocytes Therapy for Ischemic Heart Disease in Animal Model: A Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- SiRNA-mediated knockdown of TOP2B protects hiPSC-derived cardiomyocytes from doxorubicin-induced toxicity.Life sciences · 2025Article
- Stem Cells Reprogramming in Diabetes Mellitus and Diabetic Complications: Recent Advances.Current diabetes reviews · 2025Review
- Mechanisms of aging in the cardiovascular system: challenges and opportunities.Frontiers in immunology · 2025Review
- Bibliometrics of trends in global research on the roles of stem cells in myocardial fibrosis therapy.World journal of stem cells · 2024Article
- MicroPET Imaging of Riboflavin Transporter 3 Expression in Myocardial Infarction/Reperfusion Rat Models with Radiofluorinated Riboflavin.ACS pharmacology & translational science · 2024Article
- The Role of Stem Cells in the Treatment of Cardiovascular Diseases.International journal of molecular sciences · 2024Review
- TIMI frame count as a predictor of major adverse cardiovascular events during the first month after primary PCI.Caspian journal of internal medicine · 2024Article
- An Experimental and Numerical Investigation of Cardiac Tissue-Patch Interrelation.Journal of biomechanical engineering · 2023Article
- Induced pluripotent stem cell-based therapies for organ fibrosis.Frontiers in bioengineering and biotechnology · 2023Review
- Large animal models for cardiac remuscularization studies: A methodological review.Frontiers in cardiovascular medicine · 2023Review
- Contemporary Challenges of Regenerative Therapy in Patients with Ischemic and Non-Ischemic Heart Failure.Journal of cardiovascular development and disease · 2022Review
- Myocardial infarction from a tissue engineering and regenerative medicine point of view: A comprehensive review on models and treatments.Biophysics reviews · 2022Review
- The Structural and the Functional Aspects of Intercellular Communication in iPSC-Cardiomyocytes.International journal of molecular sciences · 2022Review
- Mean-Field Modeling of Brain-Scale Dynamics for the Evaluation of EEG Source-Space Networks.Brain topography · 2022Article
- Review
- In Situ Maturated Early-Stage Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Improve Cardiac Function by Enhancing Segmental Contraction in Infarcted Rats.Journal of personalized medicine · 2021Article
- Review
- Current status of hepatocyte-like cell therapy from stem cells.Surgery today · 2021Review
- Mending a broken heart: current strategies and limitations of cell-based therapy.Stem cell research & therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHuman induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have recently been shown to express key cardiac proteins and improve in vivo cardiac function when administered following myocardial infarction. However, the efficacy of hiPSC-derived cell therapies, in direct comparison to current, well-established stem cell-based therapies, is yet to be elucidated. The goal of the current study was to compare the therapeutic efficacy of human mesenchymal stem cells (hMSCs) with hiPSC-CMs in mitigating myocardial infarction (MI).
methodsMale athymic nude hyrats were subjected to permanent ligation of the left-anterior-descending (LAD) coronary artery to induce acute MI. Four experimental groups were studied: 1) control (non-MI), 2) MI, 3) hMSCs (MI+MSC), and 4) hiPSC-CMs (MI+hiPSC-derived cardiomyocytes). The hiPSC-CMs and hMSCs were labeled with superparamagnetic iron oxide (SPIO) in vitro to track the transplanted cells in the ischemic heart by high-field cardiac MRI. These cells were injected into the ischemic heart 30-min after LAD ligation. Four-weeks after MI, cardiac MRI was performed to track the transplanted cells in the infarct heart. Additionally, echocardiography (M-mode) was performed to evaluate the cardiac function. Immunohistological and western blot studies were performed to assess the cell tracking, engraftment and cardiac fibrosis in the infarct heart tissues.
resultsEchocardiography data showed a significantly improved cardiac function in the hiPSC-CMs and hMSCs groups, when compared to MI. Immunohistological studies showed expression of connexin-43, α-actinin and myosin heavy chain in engrafted hiPSC-CMs. Cardiac fibrosis was significantly decreased in hiPSC-CMs group when compared to hMSCs or MI groups. Overall, this study demonstrated improved cardiac function with decreased fibrosis with both hiPSC-CMs and hMSCs groups when compared with MI group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.